1,078 results found

The introduction of the Unified Patent Court (UPC) has brought significant changes to the European patent landscape.

The UK is rocking from the aftershocks in the wake of Brexit and the US Election and the implications of both to the UK economy. If anything is certain, it is that nothing is certain except that the sun will set and rise again the following day.

On 30 January 2020, the Court of Justice of the European Union (CJEU) issued its decision on a request for preliminary ruling ...

With the UK's withdrawal from the EU getting up a head of steam, recent government consultations and technical notices on changes to the legal and regulatory framework governing the food and drink sector provide a useful insight into the potential effects of Brexit on this sector.

On 31 January 2020, the UK left the EU although this was followed by a transition period, during which EU law continued to be applicable in the UK, unless otherwise provided by the European Union...

In this update, our competition law experts consider a number of recent competition law developments in the pharma sector in the EU, France, Germany, Spain, the UK and China.

The Department of Health and Social Care (DHSC) has consulted with industry on its plans to change the rules governing NHS spending on branded medicines...

The pharmaceutical industry has emerged from the pandemic stronger in large part due to its role in researching, producing and distributing Covid-related therapies and vaccines but also...

The Prescription Medicines Code of Practice Authority (PMCPA) has published new guidance to provide clarity on the disclosure obligations and commercial governance expected from companies in relation to package deals (Guidance).

An investigation is underway after multiple sclerosis patients in the UK reported adverse effects following a switch from the originator medicine Tysabri to its biosimilar Tyruko. Despite regulatory approval confirming no clinically meaningful differences between the two natalizumab-based treatments, subtle variations in manufacturing processes, formulation buffers, and molecular characteristics may explain why some patients have experienced worsening symptoms or side effects.

Scotland launches consultation on stricter HFSS restrictions | FSA launch campaign on allergy risks with vegan labelling | Consultation launched on fairer food labelling...

On 12 July 2005 the European Court of Justice (ECJ) upheld the validity of Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements. In particular it upheld the internal market legal base and the positive list of vitamins and minerals that can be used in supplements.

Two referrals have been made to the Court of Justice of the European Union (CJEU), one originating from the Finnish Market Court (C-119/22) and another originating from the Supreme Court Ireland (C-149/22).

The proposed simplification is intended to reduce the administrative burden on EU manufacturers of medical and in-vitro diagnostic devices and lower their compliance-related costs...

To support your food and beverage business in getting more from your risk management and insurance spend, in this insight, WTW specialists offer their takes on the state of the insurance market...

The growing use of combination therapies pairing small molecules with biologics is reshaping drug development, delivering clinically meaningful synergy and improved efficacy. However, as the science advances, so do the intellectual property and regulatory challenges, particularly where multiple stakeholders are involved in bringing these therapies to market.

On 14 November 2018 the UK Supreme Court (SC) handed down its decision in Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis, which includes a majority judgment and interesting dissenting ones.

A review of the trade in counterfeit medicines, and some associated Intellectual Property enforcement issues.